This was a prospective, randomized, open-label, blinded end point (PROBE), 30 parallel group study with two treatment arms. A total of 160 outpatients aged 61–75 years entered a 2-week wash-out period ...
Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease -13.17 mmol/L ...
Sildenafil is an orally active selective type 5 phosphodiesterase (PDE) inhibitor, and has proven to be an effective agent for the treatment of male ED. Sildenafil inhibits the breakdown of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results